Scientists at Japan’s Shibaura Institute of Technology developed vitamin K–based compounds that are up to three times more effective at converting neural stem cells into mature neurons, potentially enabling regenerative treatments for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s.
Phylloquinone (vitamin K1) and menaquinones (vitamin K2, such as MK-4 and MK-7) are best described as the active counterparts of Vitamin K. Beyond their well-known roles in blood clotting and bone metabolism, emerging research suggests that these active forms may also contribute to neuroprotection and support neuronal differentiation. To enhance this effect, researchers led by Yoshihisa Hirota and Yoshitomo Suhara combined vitamin K structures with retinoic acid–derived elements that promote neuronal growth.
Researchers also explored how vitamin K exerts its neuroprotective effects. Comparing gene activity in neural stem cells showed mGluR1 as a key driver of vitamin K–induced neuron formation; its loss in animals causes motor and synaptic deficits similar to neurodegenerative diseases.
Structural Modeling, Uptake, and Pharmacokinetics of Novel VK
Structural modeling and docking suggest that Novel VK binds to mGluR1 more strongly than natural vitamin K. Laboratory tests also show that cells absorb it more efficiently and convert it more readily into the active form, MK-4. In mouse studies, Novel VK demonstrated stable pharmacokinetics and generated substantially higher levels of MK-4 in the brain.
Commenting on the findings, Professor Yoshihisa Hirota emphasized the potential impact of the discovery. He noted that the new vitamin K analogs were about three times more effective than natural vitamin K at driving neural progenitor cells to become neurons. Because neuron loss is central to diseases like Alzheimer’s, these compounds could one day support regenerative therapies to replace lost neurons and restore brain function.
mGluR1 as a Therapeutic Target in Alzheimer’s Research and Future Directions
Researchers have only tested these findings in laboratory and animal studies so far, with no human trials yet. However, identifying the mGluR1 pathway gives researchers a clearer target for developing future brain-repair treatments. This comes as Alzheimer’s research increasingly shifts beyond symptom management toward therapies that address the underlying biology of the disease. Recent anti-amyloid drugs aim to slow early disease progression but cannot restore lost cognitive function.
If future trials confirm safety and effectiveness, vitamin K–based therapies could shift treatment from slowing neuron loss to replacing damaged neurons. Professor Yoshihisa Hirota suggests such an approach might delay Alzheimer’s progression, ease symptoms, improve quality of life, and reduce healthcare and long-term care costs.
The study was supported by several Japanese research organizations, including the Mishima Kaiun Memorial Foundation, the Suzuken Memorial Foundation, and the Japan Society for the Promotion of Science.
Read the original article on: o cafezinho
Read more:A new study suggests Wi-Fi routers may scan human bodies to accurately identify people